Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shadi Shahouri (NPI 1568457950)

Field	Value
Entity Type	Individual
Organization	Shadi Shahouri
Address	1921 N Webb Rd
City	Wichita
State	KS
ZIP	67206
Taxonomy	Rheumatology Physician
NPI Enumerated	September 13, 2005

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider bills almost exclusively to Medicare with total Medicare revenue of $1.9M and reported Medicaid revenue of none; the absence of Medicaid billing on file makes this effectively a single-payer Medicare practice in the available data. The lack of Medicaid activity suggests the provider’s patient panel and service lines are concentrated in older adults and fee-for-service Medicare beneficiaries rather than state-covered populations.

Revenue is highly concentrated in a small set of biologic-injection codes: the precomputed top 3 Medicare codes by revenue account for 54.1% of this provider’s total Medicare revenue, with J1602 contributing $451.2K (23.2%), J3262 contributing $308K (15.9%), and J0129 contributing $290.7K (15.0%). These three codes together drive more than half of the reported Medicare income, indicating the practice’s financial dependence on a narrow set of high-cost drug administrations.

The mix of top codes indicates an infusion- and biologic-focused rheumatology practice: prominent drug codes J1602, J3262, J0129, J9312, J1745 and administration-related codes such as 96365, 96413 and 96415 point to in-office infusion and parenteral biologic therapy as central services. Additional support services tied to bone health and rheumatology follow-up — including 77080 (DXA), J0897 (denosumab), and J3111 (romosozumab-aqqg) — further suggest a service line that manages inflammatory disease and osteoporosis with clinic-administered biologics and diagnostics.

Competitive standing by code is mixed: J1602 is sizable for this provider at $451.2K and ranks #74 of 1041 providers nationally (93th percentile) but is labeled as "typical, unremarkable volume for this code," while J3262 ($308K) and J0129 ($290.7K) also appear with labels of "typical, unremarkable volume" at their reported ranks. In short, the practice has meaningful national presence on several biologic products but does not appear to be a dominant outlier across those drug codes.

E/M activity shows notable concentration in higher-level office visits: 99214 generated $117.2K (6.0%) and is flagged as an "extreme outlier, far above typical national volume for this code," while 99204 ($18.9K, 1.0%) is described as "notably above typical national volume for this code." These patterns indicate a heavier-than-typical throughput of moderate- to high-complexity office encounters, consistent with chronic disease management and frequent follow-up visits.

Diagnostic and routine lab services are used heavily alongside infusion care: codes such as 80053 (930 claims, $9.3K), 85025 (910 claims, $7.3K), 86140 (830 claims, $4.2K) and 85652 (846 claims, $2.5K) appear at relatively high claim counts and are described as typical volumes for those codes. In addition, 77077 (joint survey) ranks #53 of 487 providers nationally (89th percentile) and supports a workflow that includes imaging and lab monitoring for rheumatologic and musculoskeletal patients.

The provider’s national ranking profile across many drug and infusion codes is mostly characterized as "typical, unremarkable volume," with a few exceptions in evaluation-and-management codes; this suggests steady, practice-level scale rather than a specialty national center for biologic administration. Operationally, that implies predictable service demand from a Medicare-heavy panel but not a market-leading footprint for most biologic lines.

The NPI was enumerated on 2005-09-13 (~21 years ago), indicating long tenure in practice. Combined with the concentrated Medicare revenue and established patterns of infusion, diagnostics, and frequent E/M visits, the data point to a mature, stable rheumatology practice whose financial health is closely tied to Medicare reimbursement and the administration of in-office biologic therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	41,020	$10	$451.2K
J3262	Injection, tocilizumab, 1 mg	61,600	$10	$308K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	8,550	$30	$290.7K
J9312	Injection, rituximab, 10 mg	3,150	$60	$198.4K
J0897	Injection, denosumab, 1 mg	9,660	$20	$173.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,120	$30	$159.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,350	$90	$117.2K
J3111	Injection, romosozumab-aqqg, 1 mg	13,440	$10	$107.5K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	510	$50	$23.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	210	$100	$20.5K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Shadi Shahouri — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	9	20	8,000	$30	$291.5K
J3262	4	10	60,820	$1	$243K
J3111	5	10	17,700	$10	$198.5K
J9312	3	10	2,500	$60	$194.7K
J1602	2	20	14,360	$10	$167.7K
J1745	5	20	3,110	$30	$96.9K
J0897	21	180	2,160	$20	$81.5K
86235	5	20	280	$20	$30.8K
82306	18	160	40	$30	$27.1K
96413	28	80	80	$90	$26.3K

Showing 1–10 of 46

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shadi Shahouri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Shadi Shahouri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Childrens Dentistry Of Wichita	KS	Pediatric Dentistry	$0	$32.8M
Trust Homecare, LLC	KS	Home Health Agency	$0	$28.4M
Good Shepherd Hospice Wichita LLC	KS	Community Based Hospice Care Agency	$0	$17.7M
Grene Vision Group LLC	KS	Ophthalmology Physician	$0	$6.3M
Anthem Wichita Management, LLC	KS	Alzheimer Center (Dementia Center)	$0	$4.3M
Justin Gooden	KS	Undersea and Hyperbaric Medicine (Preventive Medicine) Physician	$4.3M	$0
Timothy Shaver	KS	Rheumatology Physician	$3M	$0
Jonas Lichty	KS	Oral and Maxillofacial Surgery (Dentist)	$2.6K	$2.9M
Homestead Of Crestview Operations LLC	KS	Assisted Living Facility	$0	$2.8M
Kansas Kids Heart Center, PA	KS	Pediatric Cardiology Physician	$0	$2.7M

Shadi Shahouri — Billing Profile & Reimbursement Data

Sign up for Shadi Shahouri — Billing Profile & Reimbursement Data policy alerts

Shadi Shahouri — Billing Profile & Reimbursement Data

Sign up for Shadi Shahouri — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References